ANALISIS KORELASI KADAR HIGH DENSITY LIPOPROTEIN (HDL) DAN LOW DENSITY LIPOPROTEIN (LDL) TERHADAP Hs-CRP PADA PASIEN PROLANIS HIPERTENSI
DOI:
https://doi.org/10.51878/healthy.v5i4.15643Keywords:
HDL, LDL, Hs-CRP, hipertensi, ProlanisAbstract
Hypertension is a major risk factor for cardiovascular disease and is associated with lipid metabolism disorders and systemic inflammation. Therefore, analyzing the relationship between lipid profiles and inflammatory markers is important for supporting cardiovascular risk monitoring in patients enrolled in the Chronic Disease Management Program (Prolanis) with hypertension. This study aimed to analyze the correlation of High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) levels with high-sensitivity C-reactive protein (Hs-CRP) levels. An observational analytical study with a cross-sectional design was conducted involving 30 hypertensive patients enrolled in Prolanis. HDL and LDL levels were measured using the Homogeneous Enzymatic Colorimetric method, while Hs-CRP levels were measured using the Fluorescence Immunoassay (FIA) method. Data were analyzed using Spearman’s correlation test with a significance level of 0.05. The results showed mean HDL, LDL, and Hs-CRP levels of 35.9 mg/dL, 109.9 mg/dL, and 2.6 mg/L, respectively. No significant correlation was found between HDL and Hs-CRP (r = 0.126; p = 0.507) or between LDL and Hs-CRP (r = 0.055; p = 0.771). In conclusion, HDL and LDL levels were not significantly correlated with Hs-CRP levels in the study participants. These findings suggest that the relationship between lipid profiles and inflammation warrants further investigation, considering other clinical factors.
ABSTRAK
Hipertensi merupakan faktor risiko utama penyakit kardiovaskular yang berkaitan dengan gangguan metabolisme lipid dan inflamasi sistemik. Oleh karena itu, analisis hubungan profil lipid dengan penanda inflamasi penting untuk mendukung pemantauan risiko kardiovaskular pada pasien Program Pengelolaan Penyakit Kronis (Prolanis) hipertensi. Penelitian ini bertujuan menganalisis korelasi kadar High-Density Lipoprotein (HDL) dan Low-Density Lipoprotein (LDL) dengan kadar high-sensitivity C-reactive protein (Hs-CRP). Penelitian ini menggunakan desain analitik observasional dengan pendekatan cross-sectional pada 30 pasien Prolanis hipertensi. Pemeriksaan HDL dan LDL menggunakan metode Homogeneous Enzymatic Colorimetric, sedangkan Hs-CRP diperiksa menggunakan metode Fluorescence Immunoassay (FIA). Data dianalisis menggunakan uji korelasi Spearman dengan tingkat signifikansi 0,05. Hasil penelitian menunjukkan rerata kadar HDL sebesar 35,9 mg/dL, LDL sebesar 109,9 mg/dL, dan Hs-CRP sebesar 2,6 mg/L. Tidak ditemukan korelasi yang signifikan antara HDL dan Hs-CRP (r = 0,126; p = 0,507) maupun antara LDL dan Hs-CRP (r = 0,055; p = 0,771). Dengan demikian, kadar HDL dan LDL tidak berhubungan secara signifikan dengan kadar Hs-CRP pada responden penelitian. Temuan ini menunjukkan bahwa hubungan profil lipid dan inflamasi perlu dikaji dengan mempertimbangkan faktor klinis lainnya.
References
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020). Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 4, Article 100130. https://doi.org/10.1016/j.ajpc.2020.100130
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., & Williams, K. J. (2020). Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights. Journal of Internal Medicine, 287(5), 465–493. https://doi.org/10.1111/joim.13042
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., & Mach, F. (2022). 2022 ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis, 349, 186–229. https://doi.org/10.1016/j.atherosclerosis.2022.05.003
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2020). Efficacy and safety of LDL-lowering therapy. The Lancet, 396(10263), 1637–1643. https://doi.org/10.1016/S0140-6736(20)32233-9
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., & Catapano, A. L. (2017). Low-density lipoproteins and cardiovascular disease. European Heart Journal, 41(24), 2313–2330. https://doi.org/10.1093/eurheartj/ehz962
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm—2020 executive summary. Endocrine Practice, 26(10), 1196–1224. https://doi.org/10.4158/CS-2020-0490
Hoogeveen, R. C., & Ballantyne, C. M. (2021). Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation. Clinical Chemistry, 67(1), 143–153. https://doi.org/10.1093/clinchem/hvaa252
Libby, P. (2021). Inflammation in atherosclerosis. Nature Reviews Cardiology, 18, 591–602. https://doi.org/10.1038/s41586-021-03392-8
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., Azizi, M., Benetos, A., Borghi, C., Coca, A., Cornelissen, V., Cruickshank, J. K., Cunha, P. G., Delles, C., Dominiczak, A., ... Kreutz, R. (2023). 2023 ESH guidelines for the management of arterial hypertension. Journal of Hypertension, 41(12), 1874–2071. https://doi.org/10.1097/HJH.0000000000003480
Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223–237. https://doi.org/10.1038/s41581-019-0244-2
Nafari, A., Mohammadifard, N., Haghighatdoost, F., Nasirian, S., Najafian, J., Sadeghi, M., Roohafza, H., & Sarrafzadegan, N. (2022). High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study. BMC Cardiovascular Disorders, 22, Article 241. https://doi.org/10.1186/s12872-022-02663-0
Navar, A. M., & Fonarow, G. C. (2021). Transforming the paradigm for lipid lowering. JAMA Cardiology, 6(12), 1414. https://doi.org/10.1001/jamacardio.2021.3517
Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M., Jr. (2021). High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 18, 712–723. https://doi.org/10.1038/s41569-021-00538-z
Ridker, P. M. (2023). Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology, 153, Article 107238. https://doi.org/10.1016/j.vph.2023.107238
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA, 316(12), 1289–1297. https://doi.org/10.1001/jama.2016.13985
Su, G.-Y., Ning, N. X., Lin, K.-H., & Hwu, C.-M. (2023). Low-density lipoprotein cholesterol is not a major determinant of high-sensitivity C-reactive protein levels in people without known diabetes mellitus. Metabolic Syndrome and Related Disorders, 21(10), 567–572. https://doi.org/10.1089/met.2023.0061
Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2021). Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines, 9(7), Article 781. https://doi.org/10.3390/biomedicines9070781
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 38(6), 982–1004. https://doi.org/10.1097/HJH.0000000000002453
Wang, Y., Wang, L., Zhao, Z., Yin, S., Tang, X., & Zhang, K. (2024). The predictive role of the hs-CRP/HDL-C ratio for long-term mortality in the general population: Evidence from a cohort study. BMC Cardiovascular Disorders, 24, Article 758. https://doi.org/10.1186/s12872-024-04446-1
Zhou, B., Carrillo-Larco, R. M., Danaei, G., Riley, L. M., Paciorek, C. J., Stevens, G. A., Gregg, E. W., Bennett, J. E., Solomon, B., Singleton, R. K., Sophiea, M. K., Iurilli, M. L. C., Lhoste, V. P. F., Cowan, M. J., Savin, S., Woodward, M., Balanova, Y., Cifkova, R., Damasceno, A., ... NCD Risk Factor Collaboration (NCD-RisC). (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1
